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Background: Glutathionylation is a major post-translational modification that regulates protein function.
Results:Human glutathione transferase Omega 1 (GSTO1-1) can catalyze the deglutathionylation of protein thiols in vitro and
in cell culture.
Conclusion: GSTO1-1, but not GSTO2-2, catalyzes the deglutathionylation of actin and other proteins under physiological
conditions.
Significance: Genetic variation in GSTO1-1-catalyzed deglutathionylation may influence the function of multiple proteins in
signaling pathways.
The glutathionylation of intracellular protein thiols can pro-
tect against irreversible oxidation and can act as a redox switch
regulating metabolic pathways. In this study we discovered that
theOmega class glutathione transferaseGSTO1-1plays a signif-
icant role in the glutathionylation cycle. The catalytic activity of
GSTO1-1 was determined in vitro by assaying the deglutathio-
nylation of a synthetic peptide by tryptophan fluorescence
quenching and in T47-D epithelial breast cancer cells by both
immunoblotting and thedirect determinationof total glutathio-
nylation. Mutating the active site cysteine residue (Cys-32)
ablated the deglutathionylating activity of GSTO1-1. Further-
more,wedemonstrate that the expressionofGSTO1-1 inT47-D
cells that are devoid of endogenous GSTO1-1 resulted in a 50%
reduction in total glutathionylation levels. Mass spectrometry
and immunoprecipitation identified -actin as a protein that is
specifically deglutathionylated by GSTO1-1 in T47-D cells. In
contrast to the deglutathionylation activity, we also found that
GSTO1-1 is associated with the rapid glutathionylation of cel-
lular proteins when the cells are exposed to S-nitrosogluta-
thione. The common A140D genetic polymorphism in GSTO1
was found to have significant effects on the kinetics of both the
deglutathionylation and glutathionylation reactions. Genetic vari-
ation inGSTO1-1has been associatedwith a rangeof diseases, and
the discovery that a frequent GSTO1-1 polymorphism affects glu-
tathionylationcyclereactionsrevealsacommonmechanismwhere
it can act onmultiple proteins and pathways.
The irreversible oxidation of protein thiols to sulfonic acids
can lead to the inactivation and proteolysis of the modified
protein. However, the formation of mixed disulfides between
glutathione andprotein thiols (glutathionylation) during oxida-
tive stress provides an efficient defense against irreversible oxi-
dation as the disulfide bonds can be subsequently enzymatically
reduced or “exchanged” (1).Glutathionylation is also important
in other physiological roles as there is mounting evidence that
even in the absence of oxidative stress the selective glutathio-
nylation/deglutathionylation of specific protein thiols can con-
tribute to cell signaling and the regulation of some metabolic
pathways (2, 3). Glutathionylation has been shown to have an
impact on several cellular processes including regulation of the
cell cycle (4), apoptosis (5–7), and drug response in cancer (8)
and in the progression of neurodegeneration (9). The cohort of
proteins that are structurally and functionally modified by glu-
tathionylation is collectively known as the “disulfide proteome”
or “glutathionome” and have been recently reviewed (3, 10).
Studies of the enzymes involved in the glutathionylation
cycle have focused significantly on the glutaredoxins and related
enzymes such as thioredoxin and protein disulfide isomerase (11,
12). In addition, sulfiredoxin and glutathione transferase Pi have
been shown to catalyze the deglutathionylation and glutathiony-
lation of specific proteins, respectively (8, 13). TheOmega class
GSTs (GSTO1-12 and GSTO2-2) were discovered by bioinfor-
matics (14–16), and immunohistochemical studies identified
GSTO1-1 in a diverse range of tissues with varied expression
levels (17). Whereas GSTs from the Alpha, Mu, Pi, Theta, and
Zeta classes have a tyrosine or serine residue in the active site,
the Omega class GSTs have an active site cysteine residue and
catalyze several atypical reactions including dehydroascorbate
reductase and S-(phenacyl)glutathione reductase activities as
well as glutaredoxin activity (formerly termed thioltransferase)
(18–20). Furthermore, the active site ofGSTO1 is positioned in
a wide crevice that can potentially accommodate large sub-
strates such as proteins (14).
Since their first description, theOmega classGSTs have been
investigated in relation to a number of biologically significant
pathways and clinical disorders including drug resistance (21),
Alzheimer disease (22–24), Parkinson disease (25), vascular
dementia and stroke (26, 27), and amyotrophic lateral sclerosis
(28), the action of anti-inflammatory drugs (29), the disposition
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of arsenic (30), and susceptibility to chronic obstructive pulmo-
nary disease (31–33) and cancer (34–40). However, the mech-
anism by which the Omega GSTs mediate their effects in these
diverse settings has not been clear. In this study we show that
GSTO1-1 has significant deglutathionylation activity with a
model peptide substrate. GSTO1-1-dependent deglutathiony-
lation of cellular proteins can also be detected in cultured cell
lines. In contrast, our study found that the expression of
GSTO1-1 in cultured T47-D breast cancer cells promotes the
rapid glutathionylation of cellular proteins when the cells are
exposed to nitrosoglutathione. The discovery that GSTO1-1
participates in the glutathionylation cycle and targets specific
proteins could explain the association of GSTO1 polymor-
phisms with a diverse range of clinical disorders and provide a
novel therapeutic target.
EXPERIMENTAL PROCEDURES
Materials—Unless otherwise indicated, all chemicals were
purchased from Sigma.
Protein Expression and Purification—Human (h-) GSTO1-1
allelic variants, hGSTO2-2, hGSTK1-1, and CLIC2, were
expressed from cDNA constructs in the bacterial expression
plasmid pHUEandpurified as described previously using nickel
affinity chromatography (41).
Cell Culture—Cells lines were purchased from ATCC and
were maintained at 37 °C, 5% CO2 in RPMI media supple-
mented with 10% fetal bovine serum. T47-D cells were stably
transfected with a GSTO1-encoding pCDNA3 plasmid. Stable
expression was confirmed by immunoblotting with rabbit anti-
humanGSTO1-1 antibody. The human lymphoblastoid cell lines
expressingGSTO1variantswere gifts fromDr. JuleenCavanaugh.
Peptide Synthesis—Thepeptide used in this study (SQLWCLSN)
was synthesized by the ACRF Biomolecular Resource Facility
(BRF), John Curtin School of Medical Research, Australian
National University. The synthesized peptide was dissolved in
0.1 M ammonium acetate, pH 8.0, and glutathionylated by incu-
bation with a 10-fold molar excess of oxidized glutathione for
24 h at room temperature with constant stirring. The peptide
was then diluted in sterile water (3) before freeze-drying and
purification by HPLC before use.
Tryptophan Quenching Assay—The deglutathionylation assay
was based on a previously described procedure that recorded the
change in tryptophan fluorescence as glutathione is removed
from a model peptide (42). Fluorescence was recorded at an
excitationwavelength of 280 nmand an emissionwavelength of
356 nm at room temperature over a time period of 10–30 min.
For the deglutathionylation reaction, the reaction mix con-
tainedMcIlvaine’s buffer (2 M sodium hydrogen phosphate, 1 M
citric acid, pH 7.0), 1 mM GSH, 50  NADPH, 0.25 units of
glutathione reductase, 1 mM EDTA, 0–20 M peptide, 1.4 g
GSTO1-1.Glutathione reductase andGSTO1-1were diluted in
McIlvaine’s buffer containing 1 g/l BSA. GSH affinity was
similarly measured by varying GSH concentrations from 0 to 2
mM, maintaining protein concentration constant at 1.4 g and
substrate concentration at 5 M. Deglutathionylation activities
of GSTO2-2, CLIC2, and GSTK were tested up to an enzyme
concentration of 6 g. All measurements were recorded in
triplicate.
Glutathionylation of the peptide was measured as described
previously (42) with amodification. The reactionmixwasmade
inMcIlvaine’s buffer (described above) with 5 mMGSSG, 1 mM
EDTA, 5 M peptide, 6 g of enzyme, and 2 mM t-butylhy-
droxyperoxide, and 10 g of GSTA2-2 were added to the reac-
tion to recycle the GSH to GSSG.
Preparation of S-Nitrosoglutathione—S-Nitrosoglutathione
was synthesized as described previously (17). An equimolar
amount of reduced glutathione was mixed with sodium nitrite,
and the pH was adjusted to 1.5 with concentrated HCl. The
reaction was allowed to proceed at room temperature for 5min
followed by neutralization of the synthesized nitrosogluta-
thione (GSNO) with 5 M NaOH. The concentration of GSNO
was estimated by measuring absorbance at 544 and 332 nm on
a Cary UV spectrophotometer using extinction coefficients of
15 and 750 M1cm1, respectively.
Immunoblotting—SDS-PAGE and non-reducing SDS-PAGE
were performed as described previously by Laemmli (43). The
sample buffer was devoid of reducing agents when analyzing
glutathionylated proteins. Separated proteins were transferred
onto nitrocellulose membranes and immunodetected using
antibodies raised against human GSTO1-1, -actin (Abcam),
and glutathione (Virogen) at a 1:1000 dilution and probed with
goat anti-rabbit and goat anti mouse HRP-conjugated immu-
noglobulins (Dako). Chemiluminescence was detected by the
ECL rapid step chemiluminescence detection system (Calbio-
chem, Merck).
Total ProteinGlutathionylationAssay—Protein glutathiony-
lation was determined by a previously described method (44)
Cells were lysed in a non-reducing buffer (0.5 M Tris, 300 mM
NaCl, 1% Nonidet P-40, 50 mM N-ethylmaleimide, 2 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride), and the protein concen-
tration was determined using a BCA protein estimation kit
according tomanufacturer’s instructions (Pierce). Cellular pro-
teins (100 g) were precipitated in ice-cold acetone at 20 °C
for 2h. Precipitated proteins were collected by centrifugation
at 20,000  g for 15min and resuspended in 0.1% Triton X-100
and reduced with 5 mM tris(2-carboxyethyl)phosphine (TCEP)
for 30 min at room temperature. Reduced proteins were pre-
cipitatedwith 200mM salicylic acid and centrifuged at 20,000
g for 15 min. The eluted GSH in the supernatant was assayed
with 2,3-naphthalenedicarboxyaldehyde and compared with a
standard curve. The assay was carried out in duplicate in five
independent experiments.
Glutaredoxin Thioltransferase Assay—Reactions were car-
ried out as described previously (16). 25 g of purified protein
was added to a reaction mix containing 0.1 M Tris HCl, pH 8.0,
0.3 mMNADPH, 1 mMGSH, 1 unit glutathione reductase from
Saccharomyces cerevisiae, 0.1mg/ml bovine serumalbumin, 1.5
mMEDTA, and 0.75mM 2-hydroxyethyl disulfide. The reaction
rate was measured at 340 nm at 30 °C, and the specific activity
was calculated based on an extinction coefficient of 6.22
mM1cm1. Background rates (sample buffer only) were sub-
tracted from the enzyme-catalyzed reaction rates.
Dehydroascorbate Reductase Assay—Reactions were carried
out as previously described (18). Dehydroascorbate was pre-
pared fresh on the day and used within 3 h. A typical reaction
mix contained 200mM sodium phosphate, pH 6.85, 3mMGSH,
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and 1.5 mM dehydroascorbate. The reaction was initiated by
adding 1 g of purified protein, and the rate of the reaction was
recorded at 265 nm at 30 °C. The specific activity of the
enzymes was calculated with an extinction coefficient of 14.7
mM1cm1. Background rates (sample buffer only) were sub-
tracted from the enzyme-catalyzed reaction rates.
Glutathione Transferase Assay—Reactions were carried out
in 0.1 M sodium phosphate buffer, pH 6.5, with 1 mM GSH and
1 mM freshly made 1-chloro-2,4-dinitrobenzene. The conjuga-
tion reaction was initiated by adding 5 g of enzyme and
recorded at 340 nm at 30 °C for 10 min (45). Specific activity
was calculated with an extinction coefficient of 9.6mM1cm1.
Glutathionylation via Thiyl Radical Formation—The assay
was carried out as previously described (46). The Fe(II)ADP
complex was prepared by incubating 20 mM FeCl2 and 100 mM
ADP for at least 1 h before use. The final reactionmixwasmade
up in 0.1 M sodium potassium phosphate buffer and contained
0.2 mM NADPH, 0.5 mM GSH, 2 units/ml glutathione reduc-
tase, and 50 M hydrogen peroxide. The reaction was initiated
with premixed 0.5 mM FeCl2 and 2.5 mM ADP and recorded
spectrophotometrically at 340 nm.
Quantification of GSSG—The assay was carried out as
described previously (47). 100l of samples and standardswere
treated with 10% 2-vinylpyridine for 1 h followed by pH neu-
tralization with 6% triethanolamine. Samples were incubated
with premixed 5,5-dithiobis(nitrobenzoic acid) (0.67 mg/ml)
and glutathione reductase (250 u/ml) for 30 s to 1 min as per
protocol and mixed with NADPH (0.67 mg/ml) and immedi-
ately read at 412 nm using a microplate reader.
Immunoprecipitation—T47-D cells were treated in culture
with 50 mM N-ethylmaleimide for 30 min followed by lysis in
non-reducing buffer. 1 mg of total cell lysate protein was used
per sample as measured by BCA protein estimation. Immuno-
precipitation was carried out using Pierce cross-linking immu-
noprecipitation kit. Cellular GSHwas removed by precipitating
the proteins with 5 times the volume of acetone overnight at
20 °C. Precipitated proteins were resuspended in lysis buffer as
per the manufacturer’s instructions. Immunoprecipitated pro-
teins were separated on 12% SDS-PAGE and immunoblotted as
above. The nitrocellulose membrane was incubated with a rabbit
polyclonal anti-actin (Abcam) antibody at a 1:000 dilution for 1 h
followed by incubation with a goat anti-rabbit antibody.
Mass Spectrometry—Immunoprecipitation was performed
as described above. Proteins were vacuum-dried and resus-
pended in 7 M urea, 2 M thiourea, 20 mM Tris, 4% CHAPS.
Samples were then incubated in DTT (final concentration 100
mM) for 1 h followed by iodoacetamide (final concentration 15
mM) for 1 h in the dark and run on a 12% SDS-PAGE. The gel
was stained in Coomassie Blue R-250 overnight, and bands
absent in the T47-D/GSTO1-1 lysates were excised from the
T47-D/pCDNA3 lysate. One-dimensional nanoLC electros-
pray ionization MS/MS was carried out at the Australian Pro-
teome Analysis Facility. Data generated were submitted to
Mascot (Matrix Science Ltd, London,UK). Listed proteinswere
identified with a significance threshold of p 0.02 withMascot
cut-off of 34.
G-actin/F-actinAssay—Cellswere plated in 6-well plates and
treatedwith 1mMGSNOas described above. Cellswerewashed
twice with PBS and lysed in 1% Triton X-100. The detergent-
soluble supernatant (containingG-actin) was collected, and the
pellet (containing F-actin) was washed in PBS and resuspended
in 1 SDS sample loading buffer (48). Proteins were run on
SDS-PAGE and immunoblotted. Actin was detected after incu-
bation with anti-actin (Abcam), and the ratio of G/F actin was
determined by densitometry. Glutathionylated actin was
detected by immunoblotting with anti-glutathione antibody.
Phalloidin Staining—Cells were plated on coverslips (5 104
cells) and treated with GSNO as described. For immuno-
staining, the cells were washed with PBS to remove unattached
cells and fixed in 3.7% paraformaldehyde (in PBS) for 15 min at
room temperature. The cells were washed in PBS 3 times and
permeabilized in 0.1% Triton X-100 for 10 min at room tem-
perature. Permeabilized cells were washed in PBS and incu-
bated with 50 g/ml phalloidin-FITC stain for 1 h at room
temperature in the dark. Samples were washed extensively in
PBS and mounted on glass slides with mounting medium with
DAPI (Vectashield). Fluorescence was recorded using a confo-
cal microscope (Leica SP5).
Statistical Analysis—Data were expressed as the means 
S.E. and analyzed using Prism 4 (Graphpad software Inc.). Sta-
tistical significancewas calculated by standard t tests. All exper-
iments were performed in triplicate unless otherwise stated.
RESULTS
In Vitro Deglutathionylation by GSTO1-1—To determine if
the Omega class GSTs participate in the glutathionylation
cycle, a synthetic peptide incorporating a single cysteine resi-
due adjacent to a tryptophan residue (SQLWCLSN) was gluta-
thionylated (SG) on the cysteine residue (SQLWC[SG]LSN)
and used as a substrate (42). Deglutathionylation wasmeasured
by monitoring the change in fluorescence emitted by trypto-
phan asGSHwas removed from the neighboring cysteine. Fig. 1
shows a significant increase in fluorescence in the presence of
GSTO1-1. In contrast, the closely related GSTO2-2 isoenzyme
did not catalyze deglutathionylation of the peptide. Because
recombinant GSTO2-2 exhibited normal glutaredoxin activity
and the expected high level of dehydroascorbate reductase
activity (Table 1), we concluded it was not degraded.
We also studied two additional proteins that could poten-
tially catalyze deglutathionylation reactions. Chloride intracel-
FIGURE 1. GSTO1-1 catalyzes the deglutathionylation of a peptide sub-
strate. The increase in tryptophan fluorescence indicates the rate of peptide
(SQLWC[SG]LSN) deglutathionylation by recombinant human GSTO1-1 in
the presence of GSH. Other enzymes showed no significant activity. The
results are representative traces from three replicates. The reaction rate is
provided in Table 1.
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lular channel 2 protein (CLIC-2) is a member of the cytosolic
GST structural family and, like the Omega class GSTs, has a
cysteine residue in its proposed “active site” (49, 50). Despite
the presence of a potential active site cysteine residue, we did
not detect any deglutathionylation activity. Previous studies of
CLIC-2 have failed to identify any significant enzymatic activ-
ity. The Kappa class glutathione transferase (GSTK1-1) is
found in mitochondria and is structurally and evolutionarily
distinct from the cytosolic GSTs like GSTO1-1 (45). GSTK1-1
is structurally related to the prokaryotic disulfide bond-forming
proteins and can also be considered as a potentially active partici-
pant in the glutathionylation cycle.However, recombinanthuman
GSTK1-1didnotcatalyze thedeglutathionylationof theglutathio-
nylated peptide. We confirmed the viability of the GSTK1-1 pro-
tein by measuring its glutathione-conjugating activity with
1-chloro-2.4-dinitrobenzene (25.0  1.5 mol/min/mg).
Deglutathionylation by GSTO1-1 Variants—Our previous
studies identified several polymorphic variants of GSTO1 that
could potentially vary in their substrate affinity and have an
impact on the regulation of glutathionylation levels (15). The
specific activity and other kinetic parameters shown in Table 1
were calculated from V/[S] plots. The Asp-140 variant had a
significantly lower deglutathionylation activity (p 0.001) than
the Ala-140 isoenzyme, and this difference mainly reflected a
lower kcat. We have also previously identified an E208K poly-
morphism that is closely linked with a deletion of Glu-155 (15).
The deletion ofGlu-155 causes amarked decrease in stability of
GSTO1-1, and it is difficult to distinguish the separate effects of
the lysine substitution at position 208. In this case we have
prepared recombinant enzyme with the Lys-208 substitution
and retained the glutamate at position 155. This enzyme had a
significantly lower specific activity (p  0.001) when compared
with the normal enzyme with glutamate in position 208 (Table
1). To confirm that these differences were not due to the differen-
tial degradation of the recombinant enzymes during their prepa-
ration, we compared their glutaredoxin and dehydroascorbate
reductaseactivities.Theseactivitieswere found tobe inagreement
with our previous studies, and the values obtained for the different
variants were equivalent.
Our previous studies have shown that the active site residue
in GSTO1-1 is cysteine 32 and that mutation of Cys-32 to
Ala-32 results in the total loss of glutaredoxin and S-phenacyl-
glutathione reductase activity (16, 20). In this study we found a
similar loss of deglutathionylation activity in the C32A mutant
enzyme (Table 1), confirming the importance of cysteine 32
in the deglutathionylation reaction. Surprisingly the C32A
enzyme had increased dehydroascorbate reductase activity
comparedwith the otherGSTO1-1 isoforms. This suggests that
Cys-32 is not required for the reduction of dehydroascorbate.
We previously reported that the C32A mutation causes an
increase in the enzyme capacity to use 1-chloro-2,4-dinitroben-
zene as a substrate (16).
pH Dependence of Deglutathionylation by GSTO1-1—The
reaction conditions were found to be optimum at pH 7 with
significantly lower rates at both pH extremes (pH 4 and pH 9
data not shown).
The Expression of GSTO1-1 Caused an Abatement of Protein
Glutathionylation in T47-D Cells—In previous studies, we have
shown that T47-D cells are deficient in functional GSTO1-1 (51,
52). In the present study we compared the levels of protein gluta-
thionylation in T47-D cells transfected with either an empty
pCDNA3 plasmid vector, cells transfected with pCDNA3-
GSTO1C32A, or cells transfected with pCDNA3-GSTO1. The
absence ofGSTO1-1 expression inT47-D cells transfectedwith
empty pCDNA3 and the level of stable GSTO1-1 expression in
T47-D cells transfected with either pCDNA3-GSTO1 or
pCDNA3-GSTO1C32A is shown in Fig. 2A. The expression of
GSTO1-1 in T47-D cells reduced total glutathionylation levels
by50% in comparison cells transfected with the empty vector
or pCDNA3-GSTO1C32A (Fig. 2B). Immunoblots of T47-D
cell lysates probed with an anti-PSSG antibody are shown in
Fig. 2C. The left-hand panel shows a marked depletion of glu-
tathionylated protein in cells where GSTO1-1 is expressed.
Althoughmany proteins show a reduced level of glutathionyla-
tion in the presence of GSTO1-1, it is evident that the extent of
deglutathionylation varies between proteins (see the arrows
Fig. 2C), suggesting a degree of substrate specificity. In the
right-hand panel of Fig. 2C, the lysate was treated with 100 mM
DTT to reduce any glutathione mixed disulfides, and the gen-
eral absence of bands on this blot confirms that the antibody is
detecting specific glutathionylation. It has been previously con-
sidered that glutaredoxin was primarily responsible for deglu-
tathionylation reactions, and the present results could be
explained if the expression of GSTO1-1 resulted in an elevation
in glutaredoxin expression. Western blotting showed that this
was not the case asGSTO1-1 expression inT47-D cells resulted
in a decrease in glutaredoxin expression (Fig. 2C). It is not clear
why the level of glutaredoxin is low in GSTO1-1-expressing
cells, but it is possible that the level of glutaredoxin expression
may be regulated by the general level of protein glutathionyla-
TABLE 1
Genetic variants of GSTO1-1 exhibit significantly different deglutathionylation reaction kinetics
Data are based on triplicate measurements, and standard errors are shown.
Enzyme
Km
peptide
kcat
peptide
kcat/Km
peptide
Km
GSH
Deglutathionylation-specific
activity
Thiol
transferase-specific
activity
Dehydroascorbate
reductase
specific-activity
M s1 M1 s1 mM nmol/mg of protein/min mol/mg of protein/min mol/mg of protein/min
Ala-140/Glu-208/ Cys-32 7.9  0.97 2.8  0.28 0.35 0.4  0.09 83.4  4.4 1.0  0.03 0.1  0.03
Asp-140/Glu-208/Cys-32 3.4  0.5 1.3  0.15 0.38 0.5  0.12 48.6  2.9 1.0  0.03 0.2  0.04
Ala-140/Lys-208/Cys-32 2.6  0.49 0.4  0.07 0.15 0.3  0.05 17.8  2.53 1.0  0.03 0.1  0.04
Ala-140/Glu-208/Ala-32 NDa ND 0.6  0.09
GSTO2-2 ND 1.2  0.02 12.9  0.88
GSTKb ND ND ND
a ND, activity below the limit of detection.
b GSTK conjugation activity with CDNB was measured at 25.0  1.46 mol/mg of protein/min.
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tion or by the glutathionylation of a specific protein that is
deglutathionylated by GSTO1-1.
Targets of GSTO1-1-catalyzed Deglutathionylation in T47-D
Cells—Mass spectrometrywas used to identify specific proteins
(see arrows Fig. 2C) deglutathionylated by GSTO1-1 expressed
in T47-D cells. Glutathionylated proteins were immunopre-
cipitated from T47-D cells and T47-D cells that express
GSTO1-1. The immunoprecipitated proteins from each prep-
aration were compared by SDS-PAGE and staining with Coo-
massie Blue. Glutathionylated proteins that were present in
T47-D cells and absent from cells expressing GSTO1-1 were
excised from the gel, digested with trypsin, and analyzed by
mass spectrometry. This analysis revealed -actin and three
other potential targets of deglutathionylation by GSTO1-1
(Table 2). Because -actin is known to be a target for glutathio-
nylation (53), we specifically examined the effect of GSTO1-1
expression on the glutathionylation of -actin. As shown in
Fig. 3A, -actin that was immunoprecipitated from T47-D
cells was strongly glutathionylated, but -actin from T47-D
cells expressing GSTO1-1 was not detectably glutathionylated.
The immunoblot was subsequently probed with anti -actin to
confirm that -actin was immunoprecipitated from the
GSTO1-1-expressing cells. In an additional experiment to con-
firm this result, glutathionylated proteins were immunopre-
cipitated from T47-D cells with anti-PSSG serum, and after
SDS-PAGE they were immunoblotted with anti--actin. The
results shown in Fig. 3A, lower panel, indicate that glutathiony-
lated -actin is only present in T47-D pCDNA3 cells that are
deficient in GSTO1-1.
Deglutathionylation of Actin by GSTO1-1 Influences Its Phys-
iological Activity—Previous studies have shown that the gluta-
thionylation of globular actin (G-actin) can prevent its poly-
merization to form filaments (F-actin). To further examine the
functional effects of GSTO1-1-dependent deglutathionylation
of actin, the ratio of G-actin/F-actin was determined in T47-D
cells and T47-D GSTO1-1-expressing cells. The relative
expression of G actin was found to be decreased in the GSTO1-
1-expressing cells, causing a decrease in theG/F actin ratio (Fig.
3B). Confocal fluorescence microscopy also demonstrated the
increase in the proportion of filamentous actin in cells express-
ing GSTO1-1 (Fig. 3C).
InVitroGlutathionylationbyGSTO1-1—Theglutathionylating
activity of GSTO1-1, GSTO2-2, CLIC2, and GSTK1-1 was tested
using the unglutathionylated form of the SQLWCLSN peptide in
the presence of high GSSG concentrations. Although we
recorded a low spontaneous rate of glutathionylation (minus
enzyme control reaction, Fig. 4A), the rate only increased mar-
ginally in the presence of GSTO1-1, GSTO2-2, and CLIC2 (Fig.
FIGURE 2. Expression of GSTO1-1 causes the deglutathionylation of proteins in T47-D breast cancer cells. A, an immunoblot shows the expression of
GSTO1-1 in T47-D cells transfected with pcDNA3-empty vector, pcDNA3-GSTO1, or pcDNA3-GSTO1C32A. B, the expression of active GSTO1-1 caused a
significant reduction in total protein glutathionylation (p  0.001) compared with cells expressing GSTO1-1C32A. The values are the mean  S.E. of five
observations. C, the lower left panel shows immunoblots for glutathionylated protein comparing T47-D cells transfected with the empty pCDNA3 vector and
T47-D cells expressing active GSTO1-1. Proteins showing a marked decrease in glutathionylation are indicated by arrows. The lower right panel (C) shows that
treatment of cellular proteins with dithiothreitol removes all glutathionylation. The upper panel (C) shows glutaredoxin 1 (Grx1) expression in T47-D cells
transfected with the empty pCDNA3 vector and lower expression in T47-D cells expressing active GSTO1-1.
TABLE 2
Proteins deglutathionylated by GSTO1-1 identified by mass spectrometry
Protein NCBI number Type Cellular localization Molecular mass
kDa
Actin-B NP_001092.1 Cytoskeleton Cytoplasmic 42
Heat shock protein 70 (GRP75) NP_004125.3 Stress protein Mitochondrial 70
Heat shock protein 7C (Hsp7C) NP_006588.1 Stress protein Cytoplasmic 71
Prolactin-inducible protein NP_032869.2 Signaling, metastasis marker Cytoplasmic 16.5
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4A). The absolute rate of glutathionylation was very low when
compared with the deglutathionylating activity of GSTO1-1 (Fig.
1). These results suggest that under these conditions GSTO1-1
acts primarily as a deglutathionylating enzyme.
GSTO1-1 Promotes Glutathionylation in Cells Treated with
GSNO—Although GSNO is not a strong glutathionylating
agent in vitro (54, 55), it has previously been shown to strongly
induce glutathionylation in cultured cells (44, 56). In this study
we examined the time course of intracellular glutathionylation
after treatment with 1 mM GSNO and compared T47-D cells
transfectedwith either an empty pCDNA3 plasmid vector, cells
transfected with pCDNA3-GSTO1C32A, or cells transfected
with pCDNA3-GSTO1. The level of glutathionylation rose in
each cell line; however, over the first 30 min the increased level
of glutathionylation that occurred in cells expressing catalyti-
cally activeGSTO1-1 vastly exceeded that occurring in the con-
trol pCDNA3 and pCDNA3-GSTO1C32A-transfected T47-D
cells (Fig. 4B). Subsequently, the level of glutathionylation
declined in the GSTO1-1-expressing cells but continued to
climb slowly in both of the control cells. Thismarked difference
in response suggests that GSTO1-1 is associated with the glu-
tathionylation of proteinswhen cells are exposed to highGSNO
concentrations and subsequently catalyzes the deglutathiony-
lation of proteins when GSNO is depleted. An immunoblot of
glutathionylated proteins shows that many proteins that are
poorly glutathionylated in GSTO1-1-expressing cells become
glutathionylated after the cells are treatedwithGSNO (Fig. 4C).
This result is similar to the result shown in Fig. 3Cwhere treat-
ment of cells withGSNOcaused a decrease in filamentous actin
as a result of increased glutathionylation.
To investigate themechanism of increased glutathionylation
in GSTO1-1-expressing cells after GSNO exposure, the endog-
enous GSSG levels were measured. After 30 min the cells
expressing active GSTO1-1 had significantly higher (p  0.05)
levels of free GSSG than theGSTO1-1-deficient cells. This sug-
gests that GSTO1-1may promote the formation of GSSG as an
intermediate in the metabolism of GSNO, and the elevated
GSSG level could contribute to the increased glutathionylation
of proteins in these cells (Fig. 4D). The return of GSSG levels to
control levels after 1 h probably results from its reduction to
GSH by glutathione reductase and its efflux from the cells by
multidrug resistance-related protein (MRP1).
Glutathione Thiyl Radicals as a GSTO1-1 Substrate—Previ-
ous studies have demonstrated that glutaredoxin can react with
glutathione thiyl radicals (GS) to form a disulfide anion radical
intermediate (GRX-SSG. ) and subsequently transfer the GS to
GSH or protein thiols to formGSSG or PSSG disulfides (24). In
the present study we found that GSTO1-1 can also catalyze this
FIGURE 3. Specific deglutathionylation of -actin by GSTO1-1. A, top panel, -actin was immunoprecipitated (IP), fractionated by SDSPAGE, blotted (IB), and
probed with anti-PSSG. Middle panel, the immune precipitation of -actin was confirmed by reprobing with anti--actin. Lower panel, glutathionylated proteins
were immunoprecipitated with anti-PSSG, and the blot was probed with anti--actin. B, globular and filamentous -actin were separated from T47-D pCDNA3
cells, and T47-D GSTO1-1 cells (see “Experimental Procedures”), were blotted and probed with anti--actin. Expression of GSTO1-1 decreased the proportion
of G actin and significantly altered the G/F actin ratio. C, fluorescence microscopy revealed the high levels of filamentous actin in cells expressing GSTO1-1.
Treatment of cells with GSNO caused increased glutathionylation and the formation of G actin.
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reaction and that the rate of formation of GSSG by GSTO1-
1D140 is significantly higher (p 0.001) than the rate catalyzed
by GSTO1-1A140 (Fig. 5A). To further validate the finding, we
measured the level of glutathionylation in lymphoblastoid cells
homozygous for the Ala-140 wild type and the Asp-140 variant.
Cells expressing GSTO1-1 D140 had significantly higher basal
glutathionylation levels (p  0.05) and consistently exhibited
higher glutathionylation levels after GSNO treatment (Fig. 5B).
DISCUSSION
A comparison of the structures of GSTO1, GSTO2, CLIC2,
and glutaredoxin shown in Fig. 6 reveals several conserved fea-
tures including their thioredoxin-like domains and a glutathi-
one binding site where glutathione can form a disulfide bond
with a conserved active site cysteine residue positioned near the
amino-terminal end of helix 1. In GSTO1-1, GSTO2-2, and
glutaredoxin these structural similarities translate into func-
tional similarity indicated by their shared glutaredoxin (thiol-
transferase) activity. The close structural and functional simi-
larity suggested that GSTO1-1 and GSTO2-2may also catalyze
glutathionylation reactions. In our initial studies we found that
GSTO1-1, but not GSTO2-2, was capable of deglutathionylat-
ing a model peptide and that the activity was dependent on
Cys-32, a residue that is also required for the glutaredoxin and
S-phenacylglutathione reductase activities of GSTO1-1 (16,
20). We determined that this reaction is physiologically rele-
vant by comparing the level of glutathionylation in theGSTO1-
1-deficient T47-D breast cancer cell line with a derivative cell
line that expresses recombinantGSTO1-1.Our finding that the
expression of GSTO1-1 in T47-D cells causes a significant
reduction in the level of intracellular glutathionylation con-
firmed the results obtained with the glutathionylated peptide.
FIGURE 4. The increase in cellular glutathionylation after GSNO treatment is accelerated by GSTO1-1. A, the decrease in tryptophan fluorescence
indicates the very low rate of glutathionylation of the peptide SQLWCLSN by GSTO1-1, GSTO2-2, and CLIC2. The results are the average traces from three
replicates. B, shows that the increase in protein glutathionylation after treatment of cells with 1 mM GSNO is significantly higher in T47-D cells expressing active
GSTO1-1 than in GSTO1-1-deficient cells transfected with the empty pCDNA3 vector or the C32A mutant enzyme. The data points represent the mean  S.E.
of three replicates. C, shows an immunoblot for glutathionylated protein in untreated T47-D cells and cells treated with 1 mM GSNO. GSNO caused the
glutathionylation of several proteins that were deglutathionylated in untreated cells expressing GSTO1-1. D, the levels of GSSG are significantly higher after
GSNO treatment in T47-D cells expressing GSTO1-1.
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We suggest that the reaction proceeds by the following path
where themodel peptide represents a protein substrate and the
enzyme is recycled by the action of GSH,
GSTO CysSH-32 	 SQLWCSGLSN3 GSTO CysSG-32
	 SQLWCSHLSN (Eq. 1)
GSTO CysSG-32 	 GSH3 GSTO CysSH-32 	 GSSG
(Eq. 2)
Although GSTO2 has 68% sequence identity with GSTO1
and a conserved cysteine residue in its active site (57), it did
not exhibit any deglutathionylation activity. We previously
reported significant differences in the substrate/activity profile
of GSTO2-2 compared with GSTO1-1. For example, whereas
both enzymes exhibit glutaredoxin activity, GSTO2-2 has com-
paratively very high dehydroascorbate reductase activity andno
S-phenacylglutathione reductase activity (16, 18, 58). Thus the
observation that GSTO2-2 does not catalyze deglutathionyla-
FIGURE 5. The Asp-140 variant of GSTO1 catalyzes increased GSSG formation and increased glutathionylation of cellular protein. A, GSTO1-1A140
catalyzes the formation of GSSG from glutathione thiyl radicals (GS) at a significantly higher rate than GSTO1-1A140 (mean of three determinations  S.E.).
B, total protein glutathionylation after GSNO treatment is higher in cells expressing the GSTO1-1D140 variant.
FIGURE 6. The structure of the active sites of GSTO1-1 and Grx1 are well conserved. A, the structures of GSTO1, GSTO2, CLIC2, and Grx1 shown in a
schematic are drawn from the coordinates in PDB files 1EEM, 3Q18, 2R4V, and 1GRX, respectively. In the conserved thioredoxin fold, domain -sheet is shown
in magenta, and helicies are shown in cyan. The carboxyl-terminal helical domain of GSTO1, GSTO2, and CLIC2 is shown in green. Glutathione is shown in stick
format occupying a similar position in GSTO1 and Grx1 and forming a disulfide with the active site cysteine residue positioned near the amino-terminal end of
helix 1. In CLIC2 and Grx1 the active site Cys residues form disulfide bonds with neighboring Cys residues. B shows the conservation of active site residues.
Residues shaded pink are fully conserved, residues shaded in pink are very similar, and those residues shaded in blue are weakly similar.
Glutathione Transferase Omega 1 and Glutathionylation
25776 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288 • NUMBER 36 • SEPTEMBER 6, 2013
tion is notwithout precedent. It is also notable that theGSTO1-
C32A mutant showed increased dehydroascorbate reductase
activity over thewild type enzyme, suggesting that Cys-32 is not
required for this activity. Previous studies have shown that this
mutant also has increased activity with 1-chloro-2,4-dinitro-
benzene as a substrate (16). Clearly other components of the
active sitemust contribute to the stabilization of GSH as a reac-
tive thiolate ion. This has been shown to be the case in
GSTA1-1 where Arg-15 contributes significantly to catalysis
(59, 60) in the presence or absence of Tyr-8, the primary active
site residue.
Immunoblotting shown in Fig. 2C suggested that there may
be some substrate specificity and that some proteins may be
more susceptible to deglutathionylation by GSTO1-1 than oth-
ers. Mass spectrometry identified four proteins including -ac-
tin that appear to be deglutathionylated by GSTO1-1 (Table 2).
Immunoprecipitation of -actin from T47-D cells confirmed
the mass spectrometry and clearly demonstrated that it is spe-
cifically deglutathionylated by GSTO1-1. The deglutathionyla-
tion of -actin catalyzed by GSTO1-1 was also shown to have a
direct effect on the G/F actin ratio confirming the physiological
significance of this deglutathionylation reaction. The substrate
specificity suggested by the immunoblot in Fig. 2C is not sur-
prising as glutathionylation is known to regulate the activity of
specific proteins and metabolic pathways (3, 8, 12), and sub-
strate specificity may be an important differentiating factor
between the actions of glutaredoxin, thioredoxin, sulfiredoxin,
and GSTP1–1 that have all been reported to catalyze glutathio-
nylation cycle reactions. As a regulatory mechanism, glutathio-
nylation has been likened to phosphorylation that is dependent
on the actions of a plethora of specific kinases and phospha-
tases. The addition of GSTO1-1 to the catalogue of enzymes
participating in specific glutathionylation cycle reactions
clearly supports the view that glutathionylation is an important
and specific regulatory process. The determination of the dif-
ferent protein substrate specificities for each of the enzymes
involved in glutathionylation cycle reactions requires consider-
able further investigation.
We also considered the possibility that GSTO1-1 or GSTO2-2
may also contribute to the forward glutathionylation reaction;
however, the data derived from the peptide assay suggest that
this reaction is minor under those in vitro conditions. Interest-
ingly it is clear from the data in Fig. 4b that GSTO1-1 plays a
role in the rapid protein glutathionylation that occurs when
cells are exposed to GSNO. It has been proposed that GSNO
may enter cells indirectly via the transnitrosation of cysteine to
S-nitrosocysteine that is taken up into cells by the L-system
amino acid transporter (Fig. 7). A further transnitrosation step
with GSH can regenerate GSNO (61). Previous studies have
shown that GSNO is not a good glutathionylating agent in vitro
(54, 55), and our data (not shown) indicated that it is not a
glutathionylating substrate forGSTO1-1 in the peptide fluores-
cence assay. Thus the effect of GSTO1-1 on the protein gluta-
thionylation that occurs when cells are treated with GSNO
appears to be indirect. We found that GSNO treatment signif-
icantly elevatedGSSGconcentrations inT47-Dcells expressing
GSTO1-1 compared with untransfected T47-D cells. This
change in the redox balance could lead to increased protein
S-glutathionylation. The degradation ofGSNO is dependent on
the action of alcohol dehydrogenase class III and can generate a
number of different intermediates (Fig. 7). In the presence of
high glutathione concentrations the formation of GSSG is
favored (62). In contrast, at lowGSH concentrations the forma-
tion of glutathione disulfide-S-oxide occurs. Glutathione disul-
fide-S-oxide has been identified as a strong glutathionylating
agent. Our data suggest that GSTO1-1 may play a role in the
degradation ofGSNOto glutathionylating intermediates.How-
ever, apart from the role played by alcohol dehydrogenase class
III, none of the other reactions has thus far been attributed to
the activity of a particular enzyme (Fig. 7).
Glutaredoxin has been shown to use glutathione thiyl radi-
cals to catalyze the formation of GSSG and to glutathionylate
proteins. Our observation that GSTO1-1 can also generate
GSSG from glutathione thiyl radicals suggests that, as occurs
with the glutaredoxin-catalyzed reaction, protein thiols may
also be a target for glutathionylation via this mechanism. Thus
GSTO1-1 may contribute to the forward glutathionylation of
proteins in the presence of suitable substrates.
Kinetic analysis of the deglutathionylation reaction with the
glutathionylated peptide revealed that the Ala-140 allelic vari-
ant ofGSTO1has a significantly higher specific activity than the
Asp-140 variant. In contrast the Asp-140 variant has a higher
FIGURE 7. Pathways for the GSH-dependent metabolism of GSNO. GSNO
can be taken into cells by transnitrosation with cysteine and the L-system
amino acid transporter (61). Hypothetically GSTO1-1 could catalyze the for-
mation of glutathione disulfide from S-(N-hydroxyamino)glutathione (GS-
NH-OH) or the formation of glutathione disulfide-S-oxide (GS(O)SG; from glu-
tathione sulfinamide (GS(O)NH2). Alternatively, GSTO1-1 could catalyze the
final glutathionylation of proteins (P-SSG) by glutathione disulfide-S-oxide.
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activity in the forward glutathionylation reaction with glutathi-
one thiyl radicals as a substrate. Because glutathionylation can
influence protein structure and function, the difference in
activity and the potential difference in protein specificity
between the allelic variants of GSTO1 could provide a plausible
mechanism to explain the associations between this genetic
polymorphism and a range of disorders (22, 24, 32, 33). For
example, the A140D polymorphism is one of the major drivers
of the association between the age at onset of both Alzheimer
and Parkinson diseases with GSTO1 (22, 23), and it is conceiv-
able that differences in the glutathionylation state of specific
proteins expressed in the brain could contribute to a similar
effect on these two distinct neurological disorders.
The experiments reported here have revealed the previously
unrecognized contribution of GSTO1-1 to the deglutaththio-
nylation of proteins. Because GSTO1-1 is widely expressed in
many tissues, it appears to be capable of playing a major role in
the glutathionylation cycle. In addition, the differences in the
deglutathionylation/glutathionylation reaction kinetics that we
observed between different allelic variants of GSTO1 could
translate into distinct genetic effects on those enzymes and
pathways that are regulated by GSTO1-1.
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